search
Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a MeetingAntibody-Drug Conjugates (ADCs) have rapidly emerged as one of the most promising therapeutic classes in pharmaceuticals, particularly in oncology. By combining the targeting power of monoclonal antibodies (mAbs) with the potency of cytotoxic payloads, ADCs offer precision treatment options with reduced off-target effects.
Oct 13, 2025
Peptides are short chains of amino acids that play a natural role in many biological processes. In recent years, they have become an increasingly important class of therapeutics due to their specificity, versatility, and low toxicity. As a result, peptide APIs are now at the center of modern drug discovery and development.
Oct 01, 2025
Drug discovery and development involve multiple interconnected steps, including identifying promising candidates, developing formulations, conducting clinical research, seeking regulatory approvals, and scaling-up manufacturing.
Sep 26, 2025
Antibody-Drug Conjugates (ADCs) are rapidly gaining prominence in oncology and targeted therapeutics because they deliver highly potent drugs directly to diseased cells while minimizing collateral damage to healthy tissues.
Sep 22, 2025
Innovation has always been a vital component of the pharmaceutical industry. Today, drug discovery and development are entering a new phase, powered by advanced technologies, precision approaches, and global collaboration.
Sep 16, 2025